目的 建立住院腫瘤患者應(yīng)用酮咯酸氨丁三醇評(píng)價(jià)標(biāo)準(zhǔn),采用AHP-TOPSIS法對(duì)酮咯酸氨丁三醇進(jìn)行合理性點(diǎn)評(píng)。方法 以藥品說(shuō)明書為基礎(chǔ),結(jié)合《酮咯酸鎮(zhèn)痛專家共識(shí)》《癌癥疼痛診療規(guī)范(2018年版)》等制定酮咯酸氨丁三醇合理應(yīng)用評(píng)價(jià)細(xì)則,并利用AHP賦權(quán)TOPSIS法對(duì)中國(guó)科學(xué)院合肥腫瘤醫(yī)院2022年1月2日-2023年1月9日腫瘤患者使用酮咯酸氨丁三醇注射液的254份病例進(jìn)行點(diǎn)評(píng)。結(jié)果 在254份病例中,0.7 ≤ C_i<0.8的病例有13份,占比5.12%;0.6 ≤ C_i<0.7的病例有5份,占比1.97%;C_i<0.6的病例有236份,占比高達(dá)92.91%。結(jié)論 中國(guó)科學(xué)院合肥腫瘤醫(yī)院應(yīng)用酮咯酸氨丁三醇總體合理性有待進(jìn)一步提高,應(yīng)制定對(duì)應(yīng)的干預(yù)措施,合理規(guī)范使用酮咯酸氨丁三醇,保障患者的生命安全。

Objective To establish evaluation criteria of ketorolac tromethamine for inpatients with tumor, and the to evaluate rationality of ketorolac tromethamine by AHP-TOPSIS method. Methods Based on the drug instructions, combined with the "Expert Consensus on Ketorolac Analgesia" and "Cancer Pain Diagnosis and Treatment Specification (2018 Edition)", the detailed evaluation rules for the rational application of ketorolac tromethamine were formulated, and the AHP weighted TOPSIS method was used to evaluate 254 cases of cancer patients using Ketorolac Tromethamine Injection in Hefei Cancer Hospital, Chinese Academy of Sciences from January 2, 2022 to January 9, 2023. Results Among 254 cases, 13 cases of 0.7 ≤ C_i < 0.8 accounted for 5.12%, 5 cases of 0.6 ≤ C_i < 0.7 accounted for 1.97%, and 236 cases of C_i < 0.6 accounted for 92.91%. Conclusion The overall rationality of the application of ketorolac tromethamine in Hefei Cancer Hospital, Chinese Academy of Sciences needs to be further improved. Corresponding intervention measures should be formulated to rationally regulate the use of ketorolac tromethamine to ensure the safety of patients.

R971

國(guó)家自然科學(xué)基金資助項(xiàng)目(81703826)